Resources from the same session
1315MO - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Presenter: Alison Schram
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1316MO - BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with non-small cell lung cancer: Updated results from first-in-human phase I study
Presenter: Li Zhang
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast